[
  {
    "ts": null,
    "headline": "AbbVie's Rinvoq Shines In Hair Loss Trial",
    "summary": "More than half of high-dose patients regrew 80% of scalp",
    "url": "https://finnhub.io/api/news?id=5ab9f2f93089e97b71f6fe53256482f711ab2bb7ae7fbd053bad0a289646e208",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755808581,
      "headline": "AbbVie's Rinvoq Shines In Hair Loss Trial",
      "id": 136471497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "More than half of high-dose patients regrew 80% of scalp",
      "url": "https://finnhub.io/api/news?id=5ab9f2f93089e97b71f6fe53256482f711ab2bb7ae7fbd053bad0a289646e208"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Reports for Alphabet, Exxon Mobil & AbbVie",
    "summary": "Alphabet drives cloud and AI momentum, Exxon Mobil boosts energy projects, and AbbVie rides strong drug launches despite headwinds.",
    "url": "https://finnhub.io/api/news?id=13fed2353d5013beed9dcca4ced8cd74e5b33f9d736e8cdd8d61a01e0b790ee1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755807420,
      "headline": "Top Stock Reports for Alphabet, Exxon Mobil & AbbVie",
      "id": 136471420,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Alphabet drives cloud and AI momentum, Exxon Mobil boosts energy projects, and AbbVie rides strong drug launches despite headwinds.",
      "url": "https://finnhub.io/api/news?id=13fed2353d5013beed9dcca4ced8cd74e5b33f9d736e8cdd8d61a01e0b790ee1"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Reports Positive Phase 3 Results For RINVOQ In Alopecia Areata Study",
    "summary": "AbbVie (ABBV) recently announced positive results from pivotal studies for its drug upadacitinib, which targeted severe alopecia areata, showcasing promising therapeutic advancements. Over the last quarter, AbbVie's share price increased by 15%, coinciding with broader product announcements and a strategic dividend declaration of $1.64 per share. Despite mixed earnings reports and market fluctuations, AbbVie's advances in product development and strategic expansions may have provided support...",
    "url": "https://finnhub.io/api/news?id=6f7b251ab5bd499dbac316a5b89af51a6d650c47050ea2a8910831b58df84fbc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755799640,
      "headline": "AbbVie (ABBV) Reports Positive Phase 3 Results For RINVOQ In Alopecia Areata Study",
      "id": 136471499,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) recently announced positive results from pivotal studies for its drug upadacitinib, which targeted severe alopecia areata, showcasing promising therapeutic advancements. Over the last quarter, AbbVie's share price increased by 15%, coinciding with broader product announcements and a strategic dividend declaration of $1.64 per share. Despite mixed earnings reports and market fluctuations, AbbVie's advances in product development and strategic expansions may have provided support...",
      "url": "https://finnhub.io/api/news?id=6f7b251ab5bd499dbac316a5b89af51a6d650c47050ea2a8910831b58df84fbc"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance in Afternoon Trading",
    "summary": "Health care stocks rose Thursday afternoon, with the NYSE Health Care Index adding 0.4% and the Heal",
    "url": "https://finnhub.io/api/news?id=00143b7c25af12c057dc92d678a2008557870f026c8692d31a588de03d63b0ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755797978,
      "headline": "Sector Update: Health Care Stocks Advance in Afternoon Trading",
      "id": 136469767,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Health care stocks rose Thursday afternoon, with the NYSE Health Care Index adding 0.4% and the Heal",
      "url": "https://finnhub.io/api/news?id=00143b7c25af12c057dc92d678a2008557870f026c8692d31a588de03d63b0ca"
    }
  },
  {
    "ts": null,
    "headline": "[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Biologics and Biosimilars Market size & share revenue was valued at approximately USD 478.83 Billion in 2024 and is expected to reach USD 527.36 Billion in 2025 and is expected to reach around USD 1,320.19 Billion by 2034, at a CAGR of 10.42% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen Inc., P",
    "url": "https://finnhub.io/api/news?id=9aaef2be70e1f2d712f1b47c8b1dce64987548f13e4fff641e2d6a7b53569d78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755793800,
      "headline": "[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "id": 136467561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Biologics and Biosimilars Market size & share revenue was valued at approximately USD 478.83 Billion in 2024 and is expected to reach USD 527.36 Billion in 2025 and is expected to reach around USD 1,320.19 Billion by 2034, at a CAGR of 10.42% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen Inc., P",
      "url": "https://finnhub.io/api/news?id=9aaef2be70e1f2d712f1b47c8b1dce64987548f13e4fff641e2d6a7b53569d78"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's Patch Baldness Study Finds High Hair Coverage Rates With Investigational Drug Upadacitinib",
    "summary": "AbbVie Inc. (NYSE:ABBV) on Thursday released topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean baseline SALT score of 84.0 (approximately 16% scalp hair coverage). Alopecia areata is an autoimmune disease causing hair loss, typically in small, round patches on the scalp or other body areas",
    "url": "https://finnhub.io/api/news?id=1b30839c8bf8a1f701aa27b6cbfdcf96adfdef5e5eda38e99ba065b73dae26e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755785402,
      "headline": "AbbVie's Patch Baldness Study Finds High Hair Coverage Rates With Investigational Drug Upadacitinib",
      "id": 136467617,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) on Thursday released topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean baseline SALT score of 84.0 (approximately 16% scalp hair coverage). Alopecia areata is an autoimmune disease causing hair loss, typically in small, round patches on the scalp or other body areas",
      "url": "https://finnhub.io/api/news?id=1b30839c8bf8a1f701aa27b6cbfdcf96adfdef5e5eda38e99ba065b73dae26e5"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata",
    "summary": "AbbVie (NYSE: ABBV) today announced positive topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean baseline SALT score of 84.0 (approximately 16% scalp hair coverage).1",
    "url": "https://finnhub.io/api/news?id=0df82f9c694cb1f11cd0c9b34a0ce0dedd9ccece77ceb8da65017f493e5a33eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755779400,
      "headline": "AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata",
      "id": 136467618,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced positive topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean baseline SALT score of 84.0 (approximately 16% scalp hair coverage).1",
      "url": "https://finnhub.io/api/news?id=0df82f9c694cb1f11cd0c9b34a0ce0dedd9ccece77ceb8da65017f493e5a33eb"
    }
  },
  {
    "ts": null,
    "headline": "2 High-Yield Dividend Stocks to Buy in August and Hold for a Decade or Longer",
    "summary": "These high-yield dividend stocks are built to last.",
    "url": "https://finnhub.io/api/news?id=57ae9ee243a8dff4de813f814e155004bdb74f3760d6636f37729b5c2982b01c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755776640,
      "headline": "2 High-Yield Dividend Stocks to Buy in August and Hold for a Decade or Longer",
      "id": 136467619,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "These high-yield dividend stocks are built to last.",
      "url": "https://finnhub.io/api/news?id=57ae9ee243a8dff4de813f814e155004bdb74f3760d6636f37729b5c2982b01c"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Healthcare Fund Q2 2025 Commentary",
    "summary": "The Hartford Healthcare Fund (I Share) outperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=f8b7703fb46da00d8ea965f9f056688fcf2528cb789b78bb6f1c7c7ea46efb79",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755771900,
      "headline": "Hartford Healthcare Fund Q2 2025 Commentary",
      "id": 136458913,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/685006799/image_685006799.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The Hartford Healthcare Fund (I Share) outperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=f8b7703fb46da00d8ea965f9f056688fcf2528cb789b78bb6f1c7c7ea46efb79"
    }
  },
  {
    "ts": null,
    "headline": "Does AbbVie's US$10 Billion U.S. Manufacturing Bet Shift the Long-Term Outlook for ABBV?",
    "summary": "Earlier this month, AbbVie announced a US$195 million expansion of its North Chicago manufacturing plant to increase domestic active pharmaceutical ingredient production, forming part of a broader US$10 billion capital commitment to U.S. innovation and manufacturing capacity. This move not only supports supply chain resilience but also reflects AbbVie's emphasis on expanding U.S.-based capabilities for neuroscience, immunology, and oncology medicines. We'll examine how AbbVie's investment in...",
    "url": "https://finnhub.io/api/news?id=5e14d48f070f2280afc50895677412430d6c222ce5b8114b5d3c879a65be644a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755771677,
      "headline": "Does AbbVie's US$10 Billion U.S. Manufacturing Bet Shift the Long-Term Outlook for ABBV?",
      "id": 136452258,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Earlier this month, AbbVie announced a US$195 million expansion of its North Chicago manufacturing plant to increase domestic active pharmaceutical ingredient production, forming part of a broader US$10 billion capital commitment to U.S. innovation and manufacturing capacity. This move not only supports supply chain resilience but also reflects AbbVie's emphasis on expanding U.S.-based capabilities for neuroscience, immunology, and oncology medicines. We'll examine how AbbVie's investment in...",
      "url": "https://finnhub.io/api/news?id=5e14d48f070f2280afc50895677412430d6c222ce5b8114b5d3c879a65be644a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's Rinvoq Hits Key Endpoints in 2nd Alopecia Areata Phase 3 Study",
    "summary": "AbbVie's Rinvoq Hits Key Endpoints in 2nd Alopecia Areata Phase 3 Study",
    "url": "https://finnhub.io/api/news?id=acd42d24ba35b9a9d90ab41d8c1f25ef0ff7fd2ef2e6a56303af0e9d61a4cbf2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755768960,
      "headline": "AbbVie's Rinvoq Hits Key Endpoints in 2nd Alopecia Areata Phase 3 Study",
      "id": 136488548,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie's Rinvoq Hits Key Endpoints in 2nd Alopecia Areata Phase 3 Study",
      "url": "https://finnhub.io/api/news?id=acd42d24ba35b9a9d90ab41d8c1f25ef0ff7fd2ef2e6a56303af0e9d61a4cbf2"
    }
  },
  {
    "ts": null,
    "headline": "Interim Report H1 2025: Group Revenue and Earnings Record-High",
    "summary": "HØRSHOLM, DK / ACCESS Newswire / August 21, 2025 / Gubra (CPH:GUBRA) - Today, Gubra released its interim report for the first half of 2025. Group revenue and EBIT in the first half of 2025 were record-high and amounted to DKK 2.5 billion and DKK 2.3 ...",
    "url": "https://finnhub.io/api/news?id=48ab850e150f262b6e01d9687a663f8ac32061d6d765852991e6a7b27cc89898",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755755400,
      "headline": "Interim Report H1 2025: Group Revenue and Earnings Record-High",
      "id": 136450329,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "HØRSHOLM, DK / ACCESS Newswire / August 21, 2025 / Gubra (CPH:GUBRA) - Today, Gubra released its interim report for the first half of 2025. Group revenue and EBIT in the first half of 2025 were record-high and amounted to DKK 2.5 billion and DKK 2.3 ...",
      "url": "https://finnhub.io/api/news?id=48ab850e150f262b6e01d9687a663f8ac32061d6d765852991e6a7b27cc89898"
    }
  }
]